Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ruxolitinib Phosphate

FDA-approved product (tablet, oral), marketed as Leqselvi, Jakafi, Jakafi Xr and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ruxolitinib Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alopecia areata
  • Cancer
  • Eczematoid dermatitis
  • Graft versus host disease
  • Myelofibrosis
  • Myeloproliferative disorder
  • Neoplasm
  • Polycythemia vera
  • Primary myelofibrosis
  • Vitiligo

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor; Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ruxolitinib Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ruxolitinib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

    NCT01787552 · start 2013-05-08

    Registered record
    Registry ID
    NCT01787552
    Conditions
    Primary Myelofibrosis; Thrombocytosis; Essential Thrombocythemia; Polycythemia Vera; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Blood Coagulation Disorders; Blood Platelet Disorders; Hemorrhagic Disorders
    Interventions
    LDE225; INC424
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-05-08
    Completion
    2018-04-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Myelofibrosis; Thrombocytosis; Essential Thrombocythemia; Polycythemia Vera +6 more
    InterventionLDE225; INC424
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

    NCT01712308 · start 2013-02-21

    Registered record
    Registry ID
    NCT01712308
    Conditions
    Anemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis
    Interventions
    Sotatercept; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02-21
    Completion
    2022-05-24
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis
    InterventionSotatercept; Ruxolitinib
    PhasePhase 2
    Registry statusCompleted

  • Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

    NCT01523171 · start 2012-04-30

    Registered record
    Registry ID
    NCT01523171
    Conditions
    Hematopoietic Neoplasm
    Interventions
    SAR302503
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-04-30
    Completion
    2014-04-30
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic Neoplasm
    InterventionSAR302503
    PhasePhase 2
    Registry statusTerminated

  • Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

    NCT01445769 · start 2011-09

    Registered record
    Registry ID
    NCT01445769
    Conditions
    Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis
    InterventionRuxolitinib
    PhasePhase 2
    Registry statusCompleted

  • MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

    NCT05269771

    Registered record
    Registry ID
    NCT05269771
    Conditions
    Polycythemia Vera
    Interventions
    Ruxolitinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera
    InterventionRuxolitinib
    PhaseNot recorded
    Registry statusNo longer available